BioCentury | Jul 14, 2017
Clinical News

Immune begins Phase I/II of Ceplene in CMML

Immune Pharmaceuticals Inc. (NASDAQ:IMNP; SSE:IMNP) began a Phase I/II trial to evaluate twice-daily 0.5 mg subcutaneous Ceplene histamine dihydrochloride plus low-dose IL-2 in 15 patients with chronic myelomonocytic leukemia (CMML). Patients will receive Ceplene with...
BioCentury | Nov 18, 2013
Clinical News

Ceplene histamine regulatory update

Germany's Federal Joint Committee (G-BA) said it plans to assess 12 drugs launched before drug pricing law AMNOG came into effect in January 2011, including Vidaza azacitidine from Celgene and Pfizer and Ceplene histamine from...
BioCentury | Sep 5, 2013
Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Mouse model of atopic dermatitis-like inflammation A transgenic mouse model of atopic dermatitis could be useful for studying disease pathogenesis and identifying new treatments for...
BioCentury | Jul 15, 2013
Company News

Griffin Discoveries, Sensorion neurology news

...which include Meniere's disease and vertigo crisis. The companies will jointly map the function of histamine receptors...
BioCentury | Apr 8, 2013
Emerging Company Profile

Ziarco: Scratching the allergic itch

...inflammatory disease pathology. He added the target "doesn't have the same functions as the other histamine receptors."...
BioCentury | Oct 4, 2012
Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Transforming growth factor-a (TGFA; TGFa) shedding assay to detect G protein-coupled receptor (GPR) ligands A TGFa shedding assay could help identify GPR ligands. TGFa...
BioCentury | Jun 25, 2012
Company News

EpiCept, Meda sales and marketing update

EpiCept made several moves to save cash and extend its projected operations into 4Q12. EpiCept will receive $2.6 million in cash from Meda in exchange for relinquishing future milestones and royalties under a 2010 deal...
BioCentury | Mar 26, 2012
Clinical News

Caelyx regulatory update

EMA recommended that the manufacturing process for cancer drugs Caelyx doxorubicin from Johnson & Johnson and Ceplene histamine dihydrochloride from EpiCept be transferred to alternative facilities from the Ben Venue Laboratories Inc. facility. EMA's CHMP...
BioCentury | Jan 2, 2012
Clinical News

Ceplene histamine dihydrochloride regulatory update

EpiCept said that "adequate" supplies of Ceplene histamine dihydrochloride are available despite the cancer drug's third-party manufacturer ceasing all manufacture and distribution of medicines from the drug's manufacturing site. The manufacturer, Ben Venue Laboratories Inc.,...
BioCentury | Sep 19, 2011
Clinical News

Ceplene histamine dihydrochloride: FDA action

According to EpiCept, FDA indicated the biotech should compare Ceplene plus IL-2 vs. IL-2 monotherapy using OS as the primary endpoint as part of a registration trial in order to isolate the effect of Ceplene...
Items per page:
1 - 10 of 162